New Zealand markets close in 1 hour 32 minutes

Progenity, Inc. (PROG)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.2800+0.0400 (+3.23%)
At close: 04:00PM EST
1.2500 -0.03 (-2.34%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.2400
Open1.1700
Bid1.2400 x 36100
Ask1.2700 x 21500
Day's range1.1100 - 1.2900
52-week range0.6570 - 7.8600
Volume14,789,586
Avg. volume42,354,129
Market cap209.6M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-3.4440
Earnings date16 Mar 2022 - 21 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.00
  • GlobeNewswire

    Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology

    Dr. Bram Verstockt to present patient data establishing correlation between drug levels in colon and clinical outcomesSAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that patient data on indicators of efficacy in the treatment of gastrointestinal disorders has been accepted for oral presentation during the 34th edition of the Belgian Week of

  • GlobeNewswire

    Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22

    SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that two presentations with patient data on indicators of efficacy in the treatment of gastrointestinal disorders have been accepted by the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO), February 16-19, 2022, the world’s largest forum for IBD specialists. ECCO’s mission

  • GlobeNewswire

    Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference

    SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that the company will participate in a pre-recorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The presentation will be available on the conference website beginning at 7 a.m. Eastern / 4 a.m. Pacific on January 10, 2022. A link to the presentation will also be available